{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:37:06Z","timestamp":1784090226351,"version":"3.55.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["PICT-2014-2343"],"award-info":[{"award-number":["PICT-2014-2343"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005746","name":"Universidad Nacional del Litoral","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.clim.2021.108888","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T03:49:12Z","timestamp":1637120952000},"page":"108888","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Development of highly stable and de-immunized versions of recombinant alpha interferon: Promising candidates for the treatment of chronic and emerging viral diseases"],"prefix":"10.1016","volume":"233","author":[{"given":"Sof\u00eda In\u00e9s","family":"Giorgetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Etcheverrigaray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Terry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Searls","family":"De Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Ceaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Oggero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Federico","family":"Mufarrege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2021.108888_bb0005","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1089\/jir.2020.0188","article-title":"Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery","volume":"40","author":"Pereda","year":"2020","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.clim.2021.108888_bb0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.clim.2021.108888_bb0015","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijid.2021.03.015","article-title":"Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study","volume":"105","author":"Pandit","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.clim.2021.108888_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-020-05425-5","article-title":"Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.clim.2021.108888_bb0025","first-page":"1","article-title":"Interferon-\u03b12b treatment for COVID-19","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2021.108888_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111008","article-title":"Prevention and treatment of COVID-19: focus on interferons, chloroquine\/hydroxychloroquine, azithromycin, and vaccine","volume":"133","author":"Bakadia","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.clim.2021.108888_bb0035","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00281-017-0625-1","article-title":"Immune-mediated cytokine storm and its role in severe dengue","volume":"39","author":"Srikiatkhachorn","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.clim.2021.108888_bb0040","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature."},{"key":"10.1016\/j.clim.2021.108888_bb0045","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jped.2016.02.009","article-title":"Microcephaly and Zika virus: A clinical and epidemiological analysis of the current outbreak in Brazil","volume":"92","author":"Nunes","year":"2016","journal-title":"J. Pediatr."},{"key":"10.1016\/j.clim.2021.108888_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmni.2019.01.009","article-title":"History of arthropod-borne virus infections in French Polynesia","volume":"29","author":"Aubry","year":"2019","journal-title":"New Microbes New Infect."},{"key":"10.1016\/j.clim.2021.108888_bb0055","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11908-011-0180-1","article-title":"Chikungunya virus infection","volume":"13","author":"Simon","year":"2011","journal-title":"Curr. Infect. Dis. Rep."},{"key":"10.1016\/j.clim.2021.108888_bb0060","first-page":"e00104","article-title":"Vaccine and therapeutic options to control chikungunya virus","volume":"31","author":"Powers","year":"2017","journal-title":"Clin. Microbiol."},{"key":"10.1016\/j.clim.2021.108888_bb0065","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/jmv.24932","article-title":"Synergistic antiviral activity of Sofosbuvir and type-I interferons (\u03b1 and \u03b2) against Zika virus","volume":"90","author":"Snyder","year":"2018","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.clim.2021.108888_bb0070","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.leukres.2017.01.006","article-title":"Pegylated interferon alpha \u2013 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial","volume":"54","author":"Gowin","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/j.clim.2021.108888_bb0075","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/v10060317","article-title":"Antiviral effects of clinically-relevant interferon-\u03b1 and ribavirin regimens against dengue virus in the Hollow Fiber Infection Model (HFIM)","volume":"10","author":"Pires De Mello","year":"2018","journal-title":"Viruses."},{"key":"10.1016\/j.clim.2021.108888_bb0080","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.antiviral.2003.09.005","article-title":"In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-\u03b1 and ribavirin combination","volume":"61","author":"Briolant","year":"2004","journal-title":"Antivir. Res."},{"key":"10.1016\/j.clim.2021.108888_bb0085","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/infdis\/jiw358","article-title":"Chikungunya virus: In vitro response to combination therapy with ribavirin and interferon Alfa 2a","volume":"214","author":"Gallegos","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.clim.2021.108888_bb0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/10826068.2014.907175","article-title":"Therapeutic alpha-interferons protein: structure, production, and biosimilar","volume":"45","author":"El-Baky","year":"2015","journal-title":"Prep. Biochem. Biotechnol."},{"key":"10.1016\/j.clim.2021.108888_bb0095","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: past, current and future impact on biomedicine","volume":"6","author":"Borden","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.clim.2021.108888_bb0100","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/08977190400000833","article-title":"Human interferons alpha, beta and omega","volume":"22","author":"Bekisz","year":"2004","journal-title":"Growth Factors"},{"key":"10.1016\/j.clim.2021.108888_bb0105","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.clim.2014.04.005","article-title":"Successful interferon-alpha 2b therapy for unremitting warts in a patient with DOCK8 deficiency","volume":"153","author":"Al-Zahrani","year":"2014","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2021.108888_bb0110","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/j.1469-0691.2011.03729.x","article-title":"Development and specificities of anti-interferon neutralizing antibodies in patients with chronic hepatitis C treated with pegylated interferon-\u03b1","volume":"18","author":"Scagnolari","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.clim.2021.108888_bb0115","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jhep.2006.08.007","article-title":"Neutralizing antibodies to interferon alpha in a chronic hepatitis C patient non-responder to pegylated interferon","volume":"45","author":"Santantonio","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.clim.2021.108888_bb0120","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMc052880","article-title":"Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C","volume":"354","author":"van der Eijk","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2021.108888_bb0125","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clim.2017.01.003","article-title":"De Groot De-immunized and functional therapeutic (DeFT) versions of a long lasting recombinant alpha interferon for antiviral therapy","volume":"176","author":"Mufarrege","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2021.108888_bb0130","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.biochi.2007.10.013","article-title":"Novel long-lasting interferon alpha derivatives designed by glycoengineering","volume":"90","author":"Ceaglio","year":"2008","journal-title":"Biochimie."},{"key":"10.1016\/j.clim.2021.108888_bb0135","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jbiotec.2020.12.016","article-title":"Bifunctional GM-CSF-derived peptides as tools for O-glycoengineering and protein tagging","volume":"327","author":"de los Sales","year":"2021","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.clim.2021.108888_bb0140","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.clim.2011.11.010","article-title":"Effect of HLA DR epitope de-immunization of factor VIII in vitro and in vivo","volume":"142","author":"Moise","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2021.108888_bb0145","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.clim.2009.01.009","article-title":"Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics","volume":"131","author":"De Groot","year":"2009","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2021.108888_bb0150","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/jhep.2002.36502","article-title":"Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C","volume":"36","author":"Soza","year":"2002","journal-title":"Hepatology."},{"key":"10.1016\/j.clim.2021.108888_bb0160","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.4049\/jimmunol.160.7.3363","article-title":"Several common HLA-DR types share largely overlapping peptide binding repertoires","volume":"160","author":"Southwood","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2021.108888_bb0165","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1359-6446(05)03720-7","article-title":"Immunomics: discovering new targets for vaccines and therapeutics","volume":"11","author":"De Groot","year":"2006","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.clim.2021.108888_bb0170","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science. (80- )"},{"key":"10.1016\/j.clim.2021.108888_bb0175","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2021.108888_bb0180","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/glycob\/cwh151","article-title":"Prediction, conservation analysis, and structural characterization of mammalian mucin-type O-glycosylation sites","volume":"15","author":"Julenius","year":"2005","journal-title":"Glycobiology."},{"key":"10.1016\/j.clim.2021.108888_bb0185","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0076-6879(81)78146-1","article-title":"A convenient and rapid cytopathic effect inhibition assay for interferon","volume":"78","author":"Familletti","year":"1981","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.clim.2021.108888_bb0190","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1128\/jvi.37.2.755-758.1981","article-title":"Convenient assay for interferons","volume":"37","author":"Rubinstein","year":"1981","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2021.108888_bb0195","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/1045-1056(90)90066-9","article-title":"An in vitro bioassay for quantitation of human interferons by measurements of antiproliferative activity on a continuous human lymphoma cell line","volume":"18","author":"Nederman","year":"1990","journal-title":"Biologicals."},{"key":"10.1016\/j.clim.2021.108888_bb0200","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jpba.2006.10.023","article-title":"Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays","volume":"43","author":"Jaber","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.clim.2021.108888_bb0205","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1365-2567.2004.02076.x","article-title":"Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells","volume":"114","author":"Elkord","year":"2005","journal-title":"Immunology."},{"key":"10.1016\/j.clim.2021.108888_bb0210","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.immuni.2005.05.009","article-title":"The kinetic stability of MHC class II: peptide complexes is a key parameter that dictates immunodominance","volume":"23","author":"Lazarski","year":"2005","journal-title":"Immunity."},{"key":"10.1016\/j.clim.2021.108888_bb0215","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3389\/fimmu.2020.01301","article-title":"T-cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation\u2013updated consensus and review 2020","volume":"11","author":"Jawa","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2021.108888_bb0220","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1089\/jir.2004.24.560","article-title":"The development of a modified human IFN-\u03b12b linked to the fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection","volume":"24","author":"Jones","year":"2004","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.clim.2021.108888_bb0225","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00210-018-1517-1","article-title":"A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection","volume":"391","author":"Saleh","year":"2018","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.clim.2021.108888_bb0230","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.1218138109","article-title":"Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A","volume":"109","author":"Mazor","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2021.108888_bb0235","doi-asserted-by":"crossref","first-page":"eaag1286","DOI":"10.1126\/scitranslmed.aag1286","article-title":"Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools","volume":"9","author":"Lamberth","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.clim.2021.108888_bb0240","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5530\/jyp.2019.11.26","article-title":"Drug repurposing in antiviral research: a current scenario","volume":"11","author":"Mani","year":"2019","journal-title":"J. Young. Pharm."},{"key":"10.1016\/j.clim.2021.108888_bb0245","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/14787210.2019.1595591","article-title":"Spectrum of candidate molecules against chikungunya virus - an insight into the antiviral screening platforms","volume":"17","author":"Bhat","year":"2019","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"10.1016\/j.clim.2021.108888_bb0250","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/v9080223","article-title":"Influenza virus infection, interferon response, viral counter-response, and apoptosis","volume":"9","author":"Shim","year":"2017","journal-title":"Viruses."},{"key":"10.1016\/j.clim.2021.108888_bb0255","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01983-17","article-title":"Zika virus replication is substantially inhibited by novel favipiravir and interferon alpha combination regimens","volume":"62","author":"Pires De Mello","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.clim.2021.108888_bb0260","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1365-2893.2009.01095.x","article-title":"Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients","volume":"16","author":"Wada","year":"2009","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.clim.2021.108888_bb0265","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.autrev.2004.03.003","article-title":"Interferon induced autoimmune thyroid disease (AITD): a model for human autoimmunity","volume":"3","author":"Oppenheim","year":"2004","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clim.2021.108888_bb0270","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s10067-009-1239-3","article-title":"Pegylated interferon alfa-2B induced lupus in a patient with chronic hepatitis B virus infection: case report","volume":"28","author":"Yilmaz","year":"2009","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.clim.2021.108888_bb0275","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jmv.20506","article-title":"Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-responsive to IFN-\u03b1","volume":"78","author":"Jorns","year":"2006","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.clim.2021.108888_bb0280","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/eji.1830260929","article-title":"Epitopes recognized by neutralizing therapy-induced human anti-interferon alpha antibodies","volume":"26","author":"Nolte","year":"1996","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2021.108888_bb0285","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/jmv.21909","article-title":"Neutralizing antibodies to interferon-\u03b1 and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-\u03b1-2a and ribavirin (ANRS HC16 GAMMATRI substudy)","volume":"82","author":"Halfon","year":"2010","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.clim.2021.108888_bb0290","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.it.2007.07.011","article-title":"Immunogenicity of protein therapeutics","volume":"28","author":"De Groot","year":"2007","journal-title":"Trends Immunol."},{"key":"10.1016\/j.clim.2021.108888_bb0295","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejpb.2018.06.008","article-title":"In vitro models for immunogenicity prediction of therapeutic proteins","volume":"130","author":"Groell","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.clim.2021.108888_bb0300","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.tibtech.2018.05.008","article-title":"Evaluating and mitigating the immunogenicity of therapeutic proteins","volume":"36","author":"Sauna","year":"2018","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.clim.2021.108888_bb0305","first-page":"13","article-title":"Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity","volume":"2015","author":"Mahlangu","year":"1989","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.clim.2021.108888_bb0310","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/emboj.2013.79","article-title":"Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology","volume":"32","author":"Steentoft","year":"2013","journal-title":"EMBO J."},{"key":"10.1016\/j.clim.2021.108888_bb0315","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.biochi.2010.04.004","article-title":"Influence of carbohydrates on the stability and structure of a hyperglycosylated human interferon alpha mutein","volume":"92","author":"Ceaglio","year":"2010","journal-title":"Biochimie"},{"key":"10.1016\/j.clim.2021.108888_bb0320","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cell.2011.06.048","article-title":"Structural linkage between ligand discrimination and receptor activation by type i interferons","volume":"146","author":"Thomas","year":"2011","journal-title":"Cell."},{"key":"10.1016\/j.clim.2021.108888_bb0325","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/imr.12001","article-title":"Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation","volume":"250","author":"Piehler","year":"2012","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.clim.2021.108888_bb0330","doi-asserted-by":"crossref","first-page":"21785","DOI":"10.1074\/jbc.270.37.21785","article-title":"Configuration of the interferon-\u03b1\/\u03b2 receptor complex determines the context of the biological response","volume":"270","author":"Ghislain","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2021.108888_bb0335","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jmb.2004.05.059","article-title":"Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers","volume":"341","author":"Lamken","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.clim.2021.108888_bb0340","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/jir.2018.0131","article-title":"Fib-4 predicts early hematological adverse events induced by interferon-based triple therapy in chronic hepatitis C virus patients","volume":"39","author":"Montasser","year":"2019","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.clim.2021.108888_bb0345","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/1440-1681.12934","article-title":"Patient characteristics associated with peglyated interferon alfa-2a induced neutropenia in chronic hepatitis C patients","volume":"45","author":"Hindi","year":"2018","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.clim.2021.108888_bb0350","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11095-020-02978-7","article-title":"Pharmacokinetics versus in vitro Antiproliferative potency to design a novel Hyperglycosylated hIFN-\u03b12 biobetter","volume":"38","author":"Gugliotta","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.clim.2021.108888_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02485","article-title":"Improving immunotherapy through glycodesign","volume":"9","author":"Buettner","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2021.108888_bb0360","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5661\/bger-28-147","article-title":"Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation","volume":"28","author":"Ghaderi","year":"2012","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"10.1016\/j.clim.2021.108888_bb0365","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.carres.2014.02.004","article-title":"Glycans in immune recognition and response","volume":"389","author":"Amon","year":"2014","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.clim.2021.108888_bb0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.00021","article-title":"Glycosylated biotherapeutics: immunological effects of N-glycolylneuraminic acid","volume":"11","author":"Yehuda","year":"2020","journal-title":"Front. Immunol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661621002254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661621002254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:03:58Z","timestamp":1761494638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661621002254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":73,"alternative-id":["S1521661621002254"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2021.108888","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of highly stable and de-immunized versions of recombinant alpha interferon: Promising candidates for the treatment of chronic and emerging viral diseases","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2021.108888","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108888"}}